CAR-T vs donor immune cells for residual leukemia after transplant
Treatments studied
Part of Cancer clinical trials.
This study tests whether a therapy using your own immune cells (CAR-T) works better than donor immune cells (DLI) to remove leftover leukemia cells after a stem cell transplant. The goal is to prevent the leukemia from coming back.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 3 and 80 years old.
- After your stem cell transplant, there are still a small number of leukemia cells (0.1% or more) in your bone marrow or blood.
- You have not had a full leukemia relapse (cancer coming back) in your bone marrow or other organs.
- You are generally well enough to do most daily activities (ECOG score 0-2).
- You do not have an active infection or uncontrolled graft-versus-host disease (GVHD).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of a CAR-T cell therapy (Inaticabtagene Autoleucel) followed by your own stem cells being transplanted back into you. It is for teenagers and adults who have B-cell acute lymphoblastic leukemia (ALL) that is in first complete remission but still has tiny amounts of cancer cells (called MRD) that can be detected by sensitive tests.
This trial tests a special immune cell therapy (CAR-T) that targets CD7, a protein found on T-cell leukemia and lymphoma cells. It is for people who have very small amounts of cancer remaining after a stem cell transplant.
This trial tests a new type of CAR-T cell therapy for people with B-cell acute lymphoblastic leukemia that has returned or not responded to standard treatment. The CAR-T cells are made from a donor and modified to target the CD19 protein on leukemia cells.
This trial tests a two-step approach using donor immune cells to treat children with B-cell acute lymphoblastic leukemia (B-ALL) that has come back or not responded to standard treatments. First, a donor's CD19-targeted cells are given to bridge to a stem cell transplant, followed by CD22-targeted cells to prevent relapse.
This trial tests a CD19-targeted CAR-T cell therapy (S1904) for people with B-cell acute lymphoblastic leukemia that has come back or not responded to treatment. After CAR-T, some patients may go on to a stem cell transplant. The goal is to see if the CAR-T can lead to remission and who needs a transplant.
This trial tests a treatment plan for people with acute leukemia that has come back or not responded to treatment. It combines CAR-T therapy with a stem cell transplant from a half-matched donor and special immune cell infusions to help prevent relapse.
Hear when a new B-ALL trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.